Pay in 4 interest-free payments of $338.75 Learn more
Ships within 48 hours · Estimated delivery Nov 7 - Nov 12
the BTLA-HVEM axis is considered a promising target for cancer immunotherapy
Adenosine produced by the CD39/CD73 pathway can protect against ischemia-reperfusion injury
with C-terminal 8*His QLPPGKPEIFKCRSPNKETFTCWWRPGTDGGLPTNYSLTYHREGETLMHECPDYITGGPNSCHFGKQYTSMWRTYIMMVNATNQMGSSFSDELYVDVTYIVQPDPPLELAVEVKQPEDRKPYLWIKWSPPTLIDLKTGWFTLLYEIRLKPEKAAEWEIHFAGQQTEFKILSLHPGQKYLVQVRCKPDHGYWSAWSPATFIQIPSDFTMNDGGGSHHHHHHHH Expression System HEK293 Molecular Weight 32-36kDa Purity >95% by SDS-PAGE Endotoxin <0
Synapse Accession P45983 Antibody Type Polyclonal antibody Isotype IgG Application WB
UA-MHC HLA-A*0201/ELAGIGILTV Mart-1 Tetramer-APC Labelled Size:100T the BTLA-HVEM axis is consideredProduct Specification Species Human Amino Acid Sequence ELAGIGILTV Location: 26~35 Conjugation APC Background Antigen: Mart 1